These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 18474024)
1. Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation. Potter V; Moore J Rev Recent Clin Trials; 2008 May; 3(2):130-8. PubMed ID: 18474024 [TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437 [TBL] [Abstract][Full Text] [Related]
4. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454 [TBL] [Abstract][Full Text] [Related]
8. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Maurer K; Soiffer RJ Expert Rev Hematol; 2023; 16(12):943-962. PubMed ID: 37906445 [TBL] [Abstract][Full Text] [Related]
9. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]. Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903 [TBL] [Abstract][Full Text] [Related]
10. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Shimoni A; Nagler A Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195 [TBL] [Abstract][Full Text] [Related]
11. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia. Pang Y; Holtzman NG Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237 [TBL] [Abstract][Full Text] [Related]
13. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Maloney DG Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532 [TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Auletta JJ; Cooke KR Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239 [TBL] [Abstract][Full Text] [Related]